Skip header and navigation

Refine By

16245 records – page 1 of 1625.

ß2-adrenergic receptor Thr164Ile polymorphism, obesity, and diabetes: comparison with FTO, MC4R, and TMEM18 polymorphisms in more than 64,000 individuals.

https://arctichealth.org/en/permalink/ahliterature125626
Source
J Clin Endocrinol Metab. 2012 Jun;97(6):E1074-9
Publication Type
Article
Date
Jun-2012
Author
Mette Thomsen
Morten Dahl
Anne Tybjærg-Hansen
Børge G Nordestgaard
Author Affiliation
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
Source
J Clin Endocrinol Metab. 2012 Jun;97(6):E1074-9
Date
Jun-2012
Language
English
Publication Type
Article
Keywords
Adult
Body mass index
Cohort Studies
Denmark - epidemiology
Diabetes Mellitus - epidemiology - genetics
Female
Genetic Predisposition to Disease - epidemiology - genetics
Genotype
Humans
Male
Membrane Proteins - genetics
Obesity - epidemiology - genetics
Polymorphism, Single Nucleotide - genetics
Proteins - genetics
Receptor, Melanocortin, Type 4 - genetics
Receptors, Adrenergic, beta-2 - genetics
Risk factors
Abstract
The ß(2)-adrenergic receptor (ADRB2) influences regulation of energy balance by stimulating catecholamine-induced lipolysis in adipose tissue. The rare functional ADRB2rs1800888(Thr164Ile) polymorphism could therefore influence risk of obesity and subsequently diabetes.
We tested the hypothesis that the ADRB2rs1800888(Thr164Ile) polymorphism associates with risk of obesity and diabetes and compared effect sizes with those of FTO(rs9939609), MC4R(rs17782313), and TMEM18(rs6548238).
We conducted a population-based cohort study in Copenhagen, Denmark.
We genotyped more than 64,000 individuals from the Danish general population.
We evaluated body mass index (BMI), obesity (BMI =30 kg/m(2)), and diabetes.
Rare allele frequencies were 0.02 for T for ADRB2rs1800888(Thr164Ile), 0.40 for A for FTOrs9939609, 0.25 for C for MC4Rrs17782313, and 0.20 for T for TMEM18rs6548238. For rare vs. common homozygotes, odds ratio for obesity was 3.32 (95% confidence interval = 1.08-10.19) for ADRB2rs1800888(Thr164Ile), 1.42 (1.35-1.52) for FTOrs9939609, 1.18 (1.06-1.30) for MC4Rrs17782313, and 1.28 (1.10-1.50) for TMEM18rs6548238 (common vs. rare). Corresponding odds ratios for diabetes were 1.85 (0.24-14.29), 1.22 (1.07-1.39), 0.96 (0.80-1.16), and 1.61 (1.17-2.22), respectively. After adjustment for BMI, only TMEM18rs6548238 remained associated with diabetes. BMI was increased in rare vs. common homozygotes in FTOrs9939609, MC4Rrs17782313, and TMEM18rs6548238 (common vs. rare) but not in ADRB2rs1800888(Thr164Ile).
Our results suggest that ADRB2rs1800888(Thr164Ile) rare vs. common homozygotes are not significantly associated with an increase in BMI measured continuously but may be associated with an increased risk of obesity. Also, TMEM18rs6548238 associated with risk of diabetes after adjustment for BMI. These findings need confirmation in other studies.
PubMed ID
22466342 View in PubMed
Less detail

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

https://arctichealth.org/en/permalink/ahliterature197667
Source
Arch Intern Med. 2000 Aug 14-28;160(15):2363-8
Publication Type
Article
Author
L. Blais
A. Desgagné
J. LeLorier
Author Affiliation
Centre de Recherche, Hôtel-Dieu du CHUM, Saint-Urbain, Montreal, Quebec, Canada.
Source
Arch Intern Med. 2000 Aug 14-28;160(15):2363-8
Language
English
Publication Type
Article
Keywords
Adverse Drug Reaction Reporting Systems
Aged
Cohort Studies
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects - therapeutic use
Hypolipidemic Agents - adverse effects - therapeutic use
Long-Term Care
Male
Neoplasms - chemically induced
Quebec
Risk
Abstract
During the past 15 years there has been an exponential increase in the number of prescriptions for lipid-lowering drugs. Uncertainties remain about the long-term impact of these medications on cancer, which is particularly bothersome given that the duration of these treatments may extend for several decades.
To explore the association between 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and cancer incidence.
Using the administrative health databases of the Régie de l'Assurance-Maladie du Québec we performed a nested case-control study. We selected a cohort of 6721 beneficiaries of the health care plan of Quebec who were free of cancer for at least 1 year at cohort entry, 65 years and older, and treated with lipid-modifying agents. Cohort members were selected between 1988 and 1994 and were followed up for a median period of 2.7 years. From the cohort, 542 cases of first malignant neoplasm were identified, and 5420 controls were randomly selected. Users of HMG-CoA reductase inhibitors were compared with users of bile acid-binding resins as to their risk of cancer. Specific cancer sites were also considered.
Users of HMG-CoA reductase inhibitors were found to be 28% less likely than users of bile acid-binding resins to be diagnosed as having any cancer (rate ratio, 0.72; 95% confidence interval, 0.57-0.92). All specific cancer sites under study were found to be not or inversely associated with the use of HMG-CoA reductase inhibitors.
The results of our study provide some degree of reassurance about the safety of HMG-CoA reductase inhibitors.
Notes
Comment In: Arch Intern Med. 2001 Jun 11;161(11):146011386902
PubMed ID
10927735 View in PubMed
Less detail

[3-year follow-up of a child psychiatric cohort]

https://arctichealth.org/en/permalink/ahliterature78052
Source
Ugeskr Laeger. 2007 Apr 2;169(14):1317-21
Publication Type
Article
Date
Apr-2-2007
Author
Bilenberg Niels
Pedersen Dorthe
Author Affiliation
Odense Universitetshospital, Det Børne- og Ungdomspsykiatriske Hus. niels.bilenberg@ouh.fyns-amt.dk
Source
Ugeskr Laeger. 2007 Apr 2;169(14):1317-21
Date
Apr-2-2007
Language
Danish
Publication Type
Article
Keywords
Adolescent
Child
Child Behavior Disorders - diagnosis - therapy
Child, Preschool
Cohort Studies
Female
Follow-Up Studies
Humans
Male
Mental Disorders - classification - diagnosis - therapy
Parents
Prognosis
Questionnaires
Treatment Outcome
Abstract
INTRODUCTION: Publications on prospective follow-up studies of Danish child psychiatric cohorts are scarce. Such studies are necessary in order to be able to inform patients about the natural course and prognosis of child psychiatric disorders. MATERIALS AND METHODS: Baseline data is obtained from 110 children, ie. 91 boys and 19 girls (4-13 years old) assessed in 2 child and adolescent psychiatric outpatient clinics in Denmark. As part of the baseline assessment, the children were clinically diagnosed and covered most of the child psychopathological spectrum. Baseline information included demographic data, assessment of symptom-load by means of The Child Behavior Checklist (CBCL) and a global function score. The children in the cohort were assessed once a year using the CBCL and the Teachers Report Form (TRF). RESULTS: The symptom-load is declining, although still high during the follow-up period. The decline in total behaviour problem scores was greater in the group of children diagnosed with emotional and behavioural disorders compared to those with neuropsychiatric disorders (Attention deficits and Autism spectrum disorders). CONCLUSION: In spite of the relatively small sample size, this follow-up study identifies important issues of prognostic value in this clinical child psychiatric outpatient population. The material may be useful as a 'treatment as usual' group in future clinical outcome studies.
PubMed ID
17437695 View in PubMed
Less detail

A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study.

https://arctichealth.org/en/permalink/ahliterature49604
Source
J Clin Psychiatry. 2005 May;66(5):559-63
Publication Type
Article
Date
May-2005
Author
Kaisa M Saari
Sari M Lindeman
Kaisa M Viilo
Matti K Isohanni
Marjo-Riitta Järvelin
Liisa H Laurén
Markku J Savolainen
Hannu J Koponen
Author Affiliation
Department of Psychiatry, University of Oulu, PO Box 5000, 90014 Oulu, Finland. kaisa.saari@oulu.fi
Source
J Clin Psychiatry. 2005 May;66(5):559-63
Date
May-2005
Language
English
Publication Type
Article
Keywords
Adult
Antipsychotic Agents - adverse effects - therapeutic use
Cohort Studies
Comorbidity
Diet Therapy
Exercise
Female
Finland - epidemiology
Humans
Logistic Models
Male
Metabolic Syndrome X - epidemiology - prevention & control - therapy
Prevalence
Psychiatric Status Rating Scales
Research Support, Non-U.S. Gov't
Risk factors
Schizophrenia - diagnosis - drug therapy - epidemiology
Weight Loss
Abstract
OBJECTIVE: Schizophrenia is associated with a shortened life expectancy and increased somatic comorbidity with, e.g., cardiovascular disorders. One major risk factor for these disorders is the metabolic syndrome, which has been reported to have a higher frequency in schizophrenic patients. Our objective was to study the prevalence of metabolic syndrome in a population-based birth cohort. METHOD: The study sample consisted of 5613 members of the Northern Finland 1966 Birth Cohort who participated in the field study from 1997 to 1998. Subjects were divided into 4 diagnostic categories (DSM-III-R): (1) schizophrenia (N = 31), (2) other functional psychoses (N = 22), (3) nonpsychotic disorders (N = 105), and (4) no psychiatric hospital treatment (N = 5455, comparison group). Subjects were assessed for the presence of metabolic syndrome according to the criteria of the National Cholesterol Education Program. RESULTS: The prevalence of metabolic syndrome was higher in subjects with schizophrenia compared with the comparison group (19% vs. 6%, p = .010). The prevalence of metabolic syndrome in subjects with other psychoses was 5%. After controlling for sex, the results of logistic regression analysis showed that the risk of metabolic syndrome in schizophrenia was 3.7 (95% CI = 1.5 to 9.0). CONCLUSIONS: The high prevalence of metabolic syndrome in schizophrenia even at such a relatively young age underscores the need to select antipsychotic medications with no or little capability to induce metabolic side effects. Also, developing comprehensive efforts directed at controlling weight and diet and improving physical activity are needed.
PubMed ID
15889940 View in PubMed
Less detail

5-a reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.

https://arctichealth.org/en/permalink/ahliterature271757
Source
Cancer Causes Control. 2015 Sep;26(9):1289-97
Publication Type
Article
Date
Sep-2015
Author
Robinson D
Garmo H
Holmberg L
Stattin P
Source
Cancer Causes Control. 2015 Sep;26(9):1289-97
Date
Sep-2015
Language
English
Publication Type
Article
Keywords
5-alpha Reductase Inhibitors - adverse effects - therapeutic use
Adrenergic alpha-Antagonists - adverse effects - therapeutic use
Aged
Aged, 80 and over
Breast Neoplasms, Male - chemically induced - pathology
Cohort Studies
Humans
Male
Middle Aged
Prostatic Hyperplasia - drug therapy - pathology
Risk
Sweden
Abstract
5-a reductase inhibitors (5-ARI) have been suggested to increase the risk of male breast cancer. The aim of this study was to study the risk of breast cancer in men on 5-ARI, in men with benign prostatic hyperplasia (BPH) not on 5-ARI, and in men without BPH.
We performed a population-based cohort study in Sweden with data from The Prescribed Drug Register, The Patient Register, and The Cancer Register. Men on 5-ARI, men on a-blockers, or men who had undergone a transurethral resection of the prostate (TUR-P) prior to or during 2006-2008 were included as exposed to BPH and a specific treatment thereof. For each exposed man, five unexposed men were selected. Risk of breast cancer was calculated in Cox proportional hazard models.
There were 124,183 exposed men and 545,293 unexposed men, and during follow-up (median 6 years), 99 men with breast cancer were diagnosed. Compared to unexposed men, men on 5-ARI had a hazard ratio (HR) of breast cancer of 0.74 (95% confidence interval (CI) 0.27-2.03), men on a-blockers had HR 1.47 (95% CI 0.73-2.95), and men with a TUR-P had HR 1.99 (95% CI 1.05-3.75).
No increased risk of breast cancer was observed for men on 5-ARI. However, the increased risk of breast cancer among men who had undergone a TUR-P, a strong indicator of BPH, suggests that the endocrine milieu conducive to BPH is associated with male breast cancer.
Notes
Cites: Cancer Causes Control. 2014 Nov;25(11):1577-8225135615
Cites: N Engl J Med. 2003 Jul 17;349(3):215-2412824459
Cites: Nat Rev Urol. 2011 Sep;8(9):483-9421811224
Cites: J Androl. 2012 May-Jun;33(3):441-821757513
Cites: Clin Endocrinol (Oxf). 2013 Mar;78(3):373-822469460
Cites: Prostate Cancer Prostatic Dis. 2013 Mar;16(1):101-623165431
Cites: Ann Oncol. 2013 Jun;24(6):1434-4323425944
Cites: Eur Urol. 2013 Jul;64(1):118-4023541338
Cites: J Urol. 2013 Nov;190(5):1811-423665270
Cites: BJU Int. 2014 Apr;113(4):623-3524127818
Cites: Acta Oncol. 2001;40(4):467-7111504305
Cites: J Clin Endocrinol Metab. 2007 May;92(5):1659-6517299062
Cites: N Engl J Med. 2003 Dec 18;349(25):2387-9814681504
Cites: J Chronic Dis. 1987;40(5):373-833558716
Cites: J Clin Endocrinol Metab. 1990 Oct;71(4):929-312401718
Cites: Am J Epidemiol. 1992 Apr 1;135(7):734-481350708
Cites: N Engl J Med. 1996 Sep 12;335(11):8238778596
Cites: Am J Gastroenterol. 1998 Feb;93(2):231-39468249
Cites: N Engl J Med. 1998 Feb 26;338(9):557-639475762
Cites: Anticancer Res. 1997 Nov-Dec;17(6D):4293-79494523
Cites: Cancer Causes Control. 1998 May;9(3):269-759684707
Cites: BMJ. 2008;337:a166218845591
Cites: Breast Cancer Res Treat. 2010 Jan;119(1):185-9219330525
Cites: Nat Rev Urol. 2011 Jul;8(7):378-8421629218
Cites: BMC Public Health. 2011;11:45021658213
PubMed ID
26109464 View in PubMed
Less detail

A 5-year follow-up of signs and symptoms of TMD and radiographic findings in the elderly.

https://arctichealth.org/en/permalink/ahliterature182090
Source
Int J Prosthodont. 2003 Nov-Dec;16(6):631-4
Publication Type
Article
Author
Kaija Hiltunen
Jaakko S Peltola
Miira M Vehkalahti
Timo Närhi
Anja Ainamo
Author Affiliation
Department of Prosthodontics, Institute of Dentistry, University of Helsinki, Finland. kaija.hiltunen@helsinki.fi
Source
Int J Prosthodont. 2003 Nov-Dec;16(6):631-4
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Chi-Square Distribution
Cohort Studies
Female
Finland
Follow-Up Studies
Humans
Male
Mandibular Condyle - physiopathology - radiography
Radiography, Panoramic
Range of Motion, Articular - physiology
Sex Factors
Temporomandibular Joint - physiopathology - radiography
Temporomandibular Joint Disorders - classification - physiopathology - radiography
Abstract
The aim was to clarify the associations among subjective symptoms, clinical signs of temporomandibular disorders (TMD), and radiographic findings in the mandibular condyles of elderly people during a 5-year follow-up.
As part of a comprehensive medical survey of a random sample born in 1904, 1909, and 1914 (Helsinki Aging Study), 364 subjects living in Helsinki participated in the dental part of the examination during 1990 and 1991; after 5 years, 103 of these were reexamined. Comprehensive data on TMD were available for 94 subjects, and radiographic data were available for 88. TMD were assessed by Helkimo's anamnestic and clinical indices, and radiographic status was assessed by panoramic radiographs.
During the 5-year follow-up, reported anamnestic symptoms of TMD for men changed little (9%); among women, the change from baseline was 42%. When the unchanged indices were compared, the gender difference was obvious. At baseline, 5% of the women, but no men, had severe signs (clinical index III) of TMD. At the end of follow-up, none showed severe signs. Comparison of radiographic findings between baseline and follow-up showed no differences, nor did differences appear in associations between radiographic findings and anamnestic or clinical indices.
During the 5-year follow-up, signs and symptoms of TMD in these elderly individuals became milder or vanished. The radiographic status of the condyles remained stable, and no association appeared between radiographic findings and signs and symptoms of TMD.
PubMed ID
14714843 View in PubMed
Less detail

A 5-year follow-up study of aggression at work and psychological health.

https://arctichealth.org/en/permalink/ahliterature51790
Source
Int J Behav Med. 2005;12(4):256-65
Publication Type
Article
Date
2005
Author
Annie Hogh
Marie Engström Henriksson
Hermann Burr
Author Affiliation
Institute of Occupational Health, Lersø Parkallé 105, 2100 Copenhagen, Denmark. ah@ami.dk
Source
Int J Behav Med. 2005;12(4):256-65
Date
2005
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aggression
Cohort Studies
Denmark
Female
Humans
Interpersonal Relations
Male
Mental health
Middle Aged
Organizational Culture
Research Support, Non-U.S. Gov't
Workplace
Abstract
In a longitudinal cohort study, organizational climate and long-term effects of exposure to nasty teasing (aggression) at work were investigated. The baseline consisted of a representative sample of Danish employees in 1995 with a response rate of 80% (N = 5,652). Of these, 4,647 participated in the follow-up in 2000 (response rate 84%). In 1995, 6.3% were subjected to nasty teasing with no significant gender difference. At baseline, we found significant associations among nasty teasing, a negative organizational climate, and psychological health effects. In the follow-up analyses, associations were found between exposure to nasty teasing at baseline and psychological health problems at follow-up, even when controlled for organizational climate and psychological health at baseline and nasty teasing at follow-up. Stratified for gender, the follow-up associations were significant for women but not for men. Low coworker support and conflicts at baseline and teasing at follow-up mediated the effects on men.
PubMed ID
16262544 View in PubMed
Less detail

A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern.

https://arctichealth.org/en/permalink/ahliterature47352
Source
J Intern Med. 2003 Oct;254(4):386-90
Publication Type
Article
Date
Oct-2003
Author
R. Rosmond
S. Wallerius
P. Wanger
L. Martin
G. Holm
P. Björntorp
Author Affiliation
Cardiovascular Institute, Sahlgrenska University Hospital, Göteborg, Sweden.
Source
J Intern Med. 2003 Oct;254(4):386-90
Date
Oct-2003
Language
English
Publication Type
Article
Keywords
Angina Pectoris - epidemiology - metabolism
Biological Markers - blood
Blood pressure
Cardiovascular Diseases - epidemiology - metabolism
Cerebrovascular Accident - epidemiology - metabolism
Cohort Studies
Diabetes Mellitus, Type 2 - epidemiology - metabolism
Follow-Up Studies
Glucose - analysis
Humans
Hydrocortisone - analysis
Hypertension - epidemiology - metabolism
Incidence
Insulin - analysis
Male
Middle Aged
Myocardial Infarction - epidemiology - metabolism
Sweden - epidemiology
Testosterone - blood
Abstract
OBJECTIVES: Previous studies have suggested that abnormal levels of cortisol and testosterone might increase the risk of serious somatic diseases. To test this hypothesis, we conducted a 5-year follow-up study in middle-aged men. METHODS: A population-based cohort study conducted in 1995 amongst 141 Swedish men born in 1944, in whom a clinical examination supplemented by medical history aimed to disclose the presence of cardiovascular disease (CVD) (myocardial infarction, angina pectoris, stroke), type 2 diabetes and hypertension were performed at baseline and at follow-up in the year 2000. In addition, salivary cortisol levels were measured repeatedly over the day. Serum testosterone concentrations were also determined. Using the baseline data, an algorithm was constructed, which classified the secretion pattern of cortisol and testosterone from each individual as being normal or abnormal. RESULTS: By the end of follow-up, men with an abnormal hormone secretion pattern (n = 73) had elevated mean arterial pressure (P = 0.003), fasting insulin (P = 0.009) and insulin : glucose ratio (P = 0.005) compared with men with a normal secretion pattern (n = 68). Body mass index, waist circumference, and waist : hip ratio were significantly elevated in both groups. However, the 5-year incidence of CVD, type 2 diabetes, and hypertension were significantly higher (P
PubMed ID
12974877 View in PubMed
Less detail

5-year incidence of age-related maculopathy in the Reykjavik Eye Study.

https://arctichealth.org/en/permalink/ahliterature51922
Source
Ophthalmology. 2005 Jan;112(1):132-8
Publication Type
Article
Date
Jan-2005
Author
Fridbert Jonasson
Arsaell Arnarsson
Tunde Peto
Hiroshi Sasaki
Kazuyuki Sasaki
Alan C Bird
Author Affiliation
Department of Ophthalmology, University of Iceland, Reykjavik, Iceland. fridbert@landspitali.is
Source
Ophthalmology. 2005 Jan;112(1):132-8
Date
Jan-2005
Language
English
Publication Type
Article
Keywords
Age Distribution
Aged
Aged, 80 and over
Cohort Studies
Female
Humans
Iceland - epidemiology
Incidence
Macular Degeneration - classification - epidemiology
Male
Middle Aged
Population Surveillance
Prospective Studies
Research Support, Non-U.S. Gov't
Sex Distribution
Abstract
PURPOSE: To examine the age- and gender-specific 5-year incidence of age-related maculopathy (ARM) and age-related macular degeneration (AMD) in citizens of Reykjavik. DESIGN: Population-based, prospective cohort study. PARTICIPANTS: The cohort was a population-based random sample of citizens 50 years and older. Of 1379 eligible subjects, 1045 had a baseline examination in 1996; 846 of the 958 survivors (88.2%) had a 5-year follow-up examination in 2001. METHODS: The incidence of various characteristics of drusen and pigmentary changes that are typical of ARM were determined using the international classification and grading system for ARM and AMD. MAIN OUTCOME MEASURES: Early ARM and AMD were assessed by masked grading of stereo fundus photographs. RESULTS: Hypopigmentation developed at 5 years in 10.7% of people 50 to 59 years of age (95% confidence interval [CI], 6.9-14.4) and in 25.7% those 70 to 79 years of age (95% CI, 18.4-33.0) at baseline. Age-related macular degeneration developed in no one who was 50 to 59 years of age at baseline. Geographic atrophy (GA) developed in 4.6% (95% CI, 1.2-7.9) and exudative AMD in none of those who were 70 years and older at baseline. CONCLUSIONS: Geographic atrophy is the predominant type of AMD in Iceland, and the ratio of GA to neovascular AMD is higher than in racially similar populations.
PubMed ID
15629833 View in PubMed
Less detail

5-year morbidity among very preterm infants in relation to level of hospital care.

https://arctichealth.org/en/permalink/ahliterature119186
Source
JAMA Pediatr. 2013 Jan;167(1):40-6
Publication Type
Article
Date
Jan-2013
Author
Liisi Rautava
Janne Eskelinen
Unto Häkkinen
Liisa Lehtonen
Author Affiliation
Department of Pediatrics, Turku University Hospital, 20520 Turku, Finland. liisi.rautava@utu.fi
Source
JAMA Pediatr. 2013 Jan;167(1):40-6
Date
Jan-2013
Language
English
Publication Type
Article
Keywords
Child, Preschool
Cohort Studies
Female
Finland - epidemiology
Humans
Incidence
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases - epidemiology - etiology - therapy
Intensive Care, Neonatal
Logistic Models
Male
Odds Ratio
Outcome and Process Assessment (Health Care)
Patient transfer
Registries
Secondary Care
Tertiary Care Centers
Tertiary Healthcare
Abstract
To determine whether birth and care in the highest-level hospitals (level III) compared with birth in or postnatal transfer to lower-level hospitals (level II) are associated with 5-year morbidity in very preterm children.
A cohort study.
Finland.
All surviving 5-year-old children born very preterm (gestational age
PubMed ID
23128961 View in PubMed
Less detail

16245 records – page 1 of 1625.